Literature DB >> 10030675

Mutant p53 can provoke apoptosis in p53-deficient Hep3B cells with delayed kinetics relative to wild-type p53.

F Stähler1, K Roemer.   

Abstract

Wild-type (wt) p53 frequently induces apoptosis when expressed in tumor cells whereas mutant p53 acts as an oncoprotein and consequently, stimulates cell proliferation. We report here exceptions to that rule. p53 conformational mutant 175H and DNA contact mutant 273H provoke apoptosis in human p53-deficient Hep3B hepatoma cells with delayed kinetics relative to wt p53. Similarly, c-Myc strongly stimulates apoptosis in these cells. In contrast, viral oncoproteins E1A and E7, and the cellular oncoprotein MDM-2, fail to elicit cytocidal responses. Efficient apoptotic cell death by mutant p53 requires oligomerization as 175H and 273H with deletions between amino acid residues 326 and 347 of the oligomerization domain are nontoxic. Apoptosis by mutant or wt p53 was significantly inhibited by the serine protease inhibitor AEBSF but not by the inactive analog AEBSA. Together, these results suggest that a wt p53-independent control mechanism is operational in Hep3B cells that eliminates cells upon sensing illegitimate proliferation signals originating from certain oncoproteins, including mutant p53 and Myc. We suggest that some tumor cell types lack p53 altogether because they tolerate neither wild-type nor mutant forms of the protein.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 10030675     DOI: 10.1038/sj.onc.1202245

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  11 in total

1.  Harmine suppresses homologous recombination repair and inhibits proliferation of hepatoma cells.

Authors:  Lei Zhang; Fan Zhang; Wenjun Zhang; Lu Chen; Neng Gao; Yulong Men; Xiaojun Xu; Ying Jiang
Journal:  Cancer Biol Ther       Date:  2015-09-18       Impact factor: 4.742

2.  Expression of p57(KIP2) potently blocks the growth of human astrocytomas and induces cell senescence.

Authors:  A Tsugu; K Sakai; P B Dirks; S Jung; R Weksberg; Y L Fei; S Mondal; S Ivanchuk; C Ackerley; P A Hamel; J T Rutka
Journal:  Am J Pathol       Date:  2000-09       Impact factor: 4.307

3.  Potential biomarkers in the sera of breast cancer patients from bahawalpur, pakistan.

Authors:  Faiz-Ul-Hassan Nasim; Samina Ejaz; Muhammad Ashraf; Abdul Rehman Asif; Michael Oellerich; Gulzar Ahmad; Gulzar Ahmad Malik
Journal:  Biomark Cancer       Date:  2012-12-10

4.  Characterization of 9-nitrocamptothecin liposomes: anticancer properties and mechanisms on hepatocellular carcinoma in vitro and in vivo.

Authors:  Shunzhen Zheng; Shuang Chang; Jinli Lu; Zhihui Chen; Li Xie; Yu Nie; Bin He; Shengquan Zou; Zhongwei Gu
Journal:  PLoS One       Date:  2011-06-09       Impact factor: 3.240

5.  Characterization of the biological activity of a potent small molecule Hec1 inhibitor TAI-1.

Authors:  Lynn Y L Huang; Ying-Shuan Lee; Jiann-Jyh Huang; Chia-chi Chang; Jia-Ming Chang; Shih-Hsien Chuang; Kuo-Jang Kao; Yung-Jen Tsai; Pei-Yi Tsai; Chia-Wei Liu; Her-Sheng Lin; Johnson Y N Lau
Journal:  J Exp Clin Cancer Res       Date:  2014-01-09

6.  Vaccinia-related kinase 1 promotes hepatocellular carcinoma by controlling the levels of cell cycle regulators associated with G1/S transition.

Authors:  Namgyu Lee; Jung-Hee Kwon; Young Bae Kim; Seong-Hoon Kim; Sung Jin Park; Weiguang Xu; Hoe-Yune Jung; Kyong-Tai Kim; Hee Jung Wang; Kwan Yong Choi
Journal:  Oncotarget       Date:  2015-10-06

7.  SIRT7 regulates hepatocellular carcinoma response to therapy by altering the p53-dependent cell death pathway.

Authors:  Jie Zhao; Ann Wozniak; Abby Adams; Josiah Cox; Anusha Vittal; Jordan Voss; Brian Bridges; Steven A Weinman; Zhuan Li
Journal:  J Exp Clin Cancer Res       Date:  2019-06-13

Review 8.  Profiling of LINE-1-Related Genes in Hepatocellular Carcinoma.

Authors:  Tomoyuki Honda; Md Arifur Rahman
Journal:  Int J Mol Sci       Date:  2019-02-02       Impact factor: 5.923

9.  The association between the T309G polymorphism of the MDM2 gene and sensitivity to anticancer drug is dependent on the p53 mutational status in cellular models.

Authors:  N Faur; L Araud; A Laroche-Clary; J Kanno; J Toutain; T Yamori; J Robert; V Le Morvan
Journal:  Br J Cancer       Date:  2009-06-09       Impact factor: 7.640

10.  Splicing function of mitotic regulators links R-loop-mediated DNA damage to tumor cell killing.

Authors:  Yihan Wan; Xiaobin Zheng; Haiyang Chen; Yuxuan Guo; Hao Jiang; Xiaonan He; Xueliang Zhu; Yixian Zheng
Journal:  J Cell Biol       Date:  2015-04-27       Impact factor: 10.539

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.